Lonza has launched its TheraPEAK SfAAV Medium designed specifically for the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications. According to the company, the new chemically defined, non-animal origin medium accelerates cell growth, increases productivity, and reduces process variability and costs, for safe, scalable, gene therapies. 

In gene therapy, viral vectors are commonly used to facilitate the delivery of the gene of ...